Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel LibreOffice Calc

Historical Valuation Ratios (Summary)

Edwards Lifesciences Corp., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Price to earnings (P/E) 44.67 50.64 47.85 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16
Price to operating profit (P/OP) 39.72 44.87 42.81 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66
Price to sales (P/S) 12.83 14.68 14.21 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18
Price to book value (P/BV) 11.50 13.50 13.63 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.

Price to Earnings (P/E)

Edwards Lifesciences Corp., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Net income (loss) (in thousands) 335,300  340,100  489,500  338,200  309,500  325,200  (121,900) 310,600  280,200  274,700  242,300  249,700  7,000  225,900  282,700  206,600  (2,800) 170,100  186,100  230,200 
Earnings per share (EPS)2 2.41 2.37 2.35 1.37 1.32 1.27 1.20 1.79 1.67 1.24 1.16 1.22 1.16 1.14 1.05 0.89 0.93 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/E ratio4 44.67 50.64 47.85 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 29.13 31.42 33.80 36.79 48.49 58.45 58.36 45.61 41.83 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29
Bristol-Myers Squibb Co. 20.92 144.77 41.99 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55
CVS Health Corp. 17.39 16.78 14.94 14.44 12.88 10.69 10.20 10.94 14.15 20.65 17.46 25.50 23.08 10.05 10.69
Danaher Corp. 29.94 38.81 37.87 39.26 44.49 46.61 41.91 35.88 38.34 40.31 41.93 37.63 29.77 25.70 27.06 27.78 27.25
Elevance Health Inc. 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96 15.55 18.14 16.19 21.45 15.64 14.84 14.70 15.44
Intuitive Surgical Inc. 59.94 71.86 69.15 89.95 87.47 82.17 70.73 44.27 48.72 49.80 51.02 53.16 53.03 73.32 73.33 69.50 70.95
Medtronic PLC 46.56 55.13 42.80 32.34 26.30 25.38 31.86 32.75 28.78 25.11 57.38 41.16 37.80 37.82 21.55 26.35 29.96
UnitedHealth Group Inc. 26.03 27.92 27.41 23.06 20.54 17.70 16.88 19.91 20.48 17.79 17.98 17.93 21.09 21.18 20.91 20.02 20.77

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
EPS = (Net income (loss)Q4 2021 + Net income (loss)Q3 2021 + Net income (loss)Q2 2021 + Net income (loss)Q1 2021) ÷ No. shares of common stock outstanding
= (335,300,000 + 340,100,000 + 489,500,000 + 338,200,000) ÷ 623,207,437 = 2.41

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 107.73 ÷ 2.41 = 44.67

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Operating Profit (P/OP)

Edwards Lifesciences Corp., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Operating income (loss) (in thousands) 374,400  390,300  542,100  383,500  351,400  357,800  (169,700) 358,100  310,800  294,300  267,500  274,200  (5,300) 248,900  252,100  252,500  342,200  214,000  241,000  298,300 
Operating profit per share2 2.71 2.67 2.62 1.48 1.44 1.38 1.28 1.99 1.83 1.33 1.26 1.23 1.20 1.75 1.69 1.66 1.74 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/OP ratio4 39.72 44.87 42.81 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 24.45 26.84 29.01 31.39 40.69 45.82 45.19 35.87 34.03 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88
Bristol-Myers Squibb Co. 19.84 39.45 33.97 27.33 24.42 13.51 10.89 13.68 16.16 19.56 27.48 23.10 28.87
CVS Health Corp. 10.43 9.43 7.87 7.61 6.65 5.89 5.98 6.19 7.83 9.44 8.02 15.80 18.65 12.59 11.14 6.90 7.44
Danaher Corp. 25.14 32.12 30.83 32.62 36.91 46.28 43.09 35.22 34.47 29.97 30.85 26.85 23.18 20.95 21.72 22.58 22.48
Elevance Health Inc. 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55 12.60 14.74 12.58 15.87 15.01 14.22 14.34 14.81
Intuitive Surgical Inc. 56.11 67.95 69.51 89.18 88.37 83.88 71.30 43.68 48.89 50.00 49.12 51.89 49.87 48.90 50.69 46.82 44.40
Medtronic PLC 37.44 49.88 42.55 35.86 26.29 21.01 23.52 22.21 21.26 19.74 21.13 20.04 17.64 16.73 17.82 19.53 22.64
UnitedHealth Group Inc. 18.77 19.63 19.05 16.12 14.12 12.35 11.85 13.80 14.40 12.43 12.51 12.48 14.58 15.82 15.19 14.17 14.42

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
Operating profit per share = (Operating income (loss)Q4 2021 + Operating income (loss)Q3 2021 + Operating income (loss)Q2 2021 + Operating income (loss)Q1 2021) ÷ No. shares of common stock outstanding
= (374,400,000 + 390,300,000 + 542,100,000 + 383,500,000) ÷ 623,207,437 = 2.71

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 107.73 ÷ 2.71 = 39.72

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Sales (P/S)

Edwards Lifesciences Corp., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Net sales (in thousands) 1,329,700  1,310,200  1,376,000  1,216,600  1,191,700  1,140,900  925,000  1,128,700  1,174,100  1,094,000  1,086,900  993,000  977,700  906,600  943,700  894,800  888,500  821,500  841,800  883,500 
Sales per share2 8.40 8.16 7.90 7.20 7.02 7.01 6.95 7.24 6.93 6.64 6.35 6.11 5.97 5.79 5.65 5.45 5.45 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/S ratio4 12.83 14.68 14.21 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.78 5.38 5.36 5.64 6.30 6.13 5.77 5.09 4.83 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84
Bristol-Myers Squibb Co. 3.16 2.85 3.44 3.28 3.16 3.66 3.97 4.45 5.52 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02
CVS Health Corp. 0.47 0.45 0.39 0.40 0.35 0.32 0.32 0.30 0.37 0.38 0.33 0.36 0.39 0.42 0.37 0.36 0.38
Danaher Corp. 6.37 7.91 7.72 7.27 7.01 8.15 7.48 6.34 6.29 5.32 5.43 4.67 3.97 3.62 3.74 3.77 3.70
Elevance Health Inc. 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74 0.67 0.77 0.69 0.88 0.79 0.72 0.68 0.67
Intuitive Surgical Inc. 17.89 22.12 21.73 23.19 21.29 20.09 18.44 13.33 15.01 15.41 15.28 15.83 16.06 16.36 17.01 16.16 14.97
Medtronic PLC 5.57 5.71 5.43 5.11 4.36 4.34 4.82 4.72 4.36 4.04 4.27 4.35 3.92 3.57 3.65 3.62 4.06
UnitedHealth Group Inc. 1.58 1.55 1.47 1.49 1.24 1.18 1.17 1.12 1.18 1.00 1.00 0.98 1.12 1.22 1.17 1.09 1.10

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
Sales per share = (Net salesQ4 2021 + Net salesQ3 2021 + Net salesQ2 2021 + Net salesQ1 2021) ÷ No. shares of common stock outstanding
= (1,329,700,000 + 1,310,200,000 + 1,376,000,000 + 1,216,600,000) ÷ 623,207,437 = 8.40

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 107.73 ÷ 8.40 = 12.83

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Book Value (P/BV)

Edwards Lifesciences Corp., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Stockholders’ equity (in thousands) 5,835,900  5,541,300  5,133,300  4,658,400  4,574,300  4,210,300  3,839,100  3,901,100  4,148,300  3,814,800  3,500,300  3,447,500  3,140,400  3,361,300  3,164,200  3,245,700  2,956,200  3,162,500  2,939,600  2,742,700 
Book value per share (BVPS)2 9.36 8.88 8.24 7.49 7.32 6.76 6.17 6.30 6.61 6.10 5.61 5.51 5.04 5.36 5.04 5.13 4.69 4.98 4.64 4.36
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/BV ratio4 11.50 13.50 13.63 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.75 6.61 6.38 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42
Bristol-Myers Squibb Co. 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36
CVS Health Corp. 1.83 1.71 1.47 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25 1.29 2.17 1.95 1.73 1.88 1.94 2.34 2.38
Danaher Corp. 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88 2.80 2.56 2.65 2.61 2.58 2.47 2.35 2.42
Elevance Health Inc. 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15 2.82 2.45 2.24 2.26 2.24 2.04 1.84 1.82
Intuitive Surgical Inc. 8.59 10.64 10.35 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68 8.96 9.30 10.03 9.71 9.91 8.35 7.62 7.21
Medtronic PLC 3.26 3.14 3.02 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59 2.31 2.11 2.10 2.14 2.40 2.27 1.96 2.34
UnitedHealth Group Inc. 6.27 6.13 5.76 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37 4.89 5.32 5.13 4.72 4.59 4.55 4.37 4.01

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 5,835,900,000 ÷ 623,207,437 = 9.36

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 107.73 ÷ 9.36 = 11.50

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.